Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy

Bibliography

• Fukagawa M, Hamada Y, Nakanishi S, The kidney and bone metabolism: a nephrologist's point of view. J Bone Miner Metab 2006;24:434-8
   PubMed Web of Science ®Google Scholar
• Bergstrand H. Parathyreoideastudien. II. Uber Tumoren und hyperplastische Zustande der Nebenschilddrusen. Acta Med Scand 1921;54:539-600
   Google Scholar
• Hubbard RS, Wentworth JA. A case of metastatic calcification associated with chronic nephritis and hyperplasia of the parathyroids. Proc Soc Expert Biol Med 1921;18:307-8
   Google Scholar
• Albright F, Drake TG, Sulkowitch HW. Renal osteitis fibrosa cyctica: report of case with discussion of metabolic aspects. Bull John Hopkins Med J 1937;60:377-85
   Google Scholar
• Moe S, Drueke T, Cunningham J, Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcome (KDIGO). Kidney Int 2006;69:1945-53
   PubMed Web of Science ®Google Scholar
• Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol 2011;15:797-809
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical guidelines. Am J Kidney Dis 2003;42(Suppl 3):S1-S201
   PubMed Web of Science ®Google Scholar
• Barreto FC, Barreto DV, Moyses RM, K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008;73:771-7
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Yamato H, Nii-Kono T, Insufficiency of PTH action on bone in uremia. Kidney Int 2006;70(Suppl 102):S34-6
   PubMedGoogle Scholar
• Kidney disease: improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guidelone for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76(Suppl 113):S1-S130
   Google Scholar
• Guideline working group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Aphr Dial 2008;12:514-25
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Yokoyama K, Koiwa F, Clinical practice guideline for the management of Chronic Kidney disease-mineral and bone disorder (CKD-MBD). Ther Aphr Dial; In press
   Google Scholar
• Taniguchi M, Fukagawa M, Fujii N, Impact of mineral metabolism on mortality in hemodialysis patients: serum phosphate level should be controlled firstly and consistently. Ther Aphr Dial; In press
   Google Scholar
• Slatopolsky E, Gradowska L, Kashemsant C, The control of phosphate excretion in uremia. J Clin Invest 1966;45:672-7
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Caglar S, Pennell JP, On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971;50:492-9
   PubMed Web of Science ®Google Scholar
• Portale AA, Halloran BP, Murphy MM, Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. J Clin Invest 1986;77:7-12
   PubMed Web of Science ®Google Scholar
• Yi H, Fukagawa M, Yamato H, Preventio of enhanced parathyroid hormone synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Nephron 1995;70:242-8
   PubMed Web of Science ®Google Scholar
• Almaden Y, Hernandez A, Torregrosa V, High phosphate level directly stimulate sparathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998;9:1845-52
   PubMed Web of Science ®Google Scholar
• Sera-Brown A, Silver J, Brewer G, Identification of AUF1 as a parathyroid hormone mRNA 3'-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J Biol Chem 2000;275:7424-9
   PubMed Web of Science ®Google Scholar
• Shimada T, Mizutani S, Muto T, Cloning and characterization as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-5
   PubMed Web of Science ®Google Scholar
• ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-8
   PubMed Web of Science ®Google Scholar
• Komaba H, Fukagawa M. FGF23-parathyroid interaction. Kidney Int 77:292-8.2010
   PubMed Web of Science ®Google Scholar
• Perwad F, Zhang MY, Tenenhouse HS, Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007;293:F1577-83
   PubMed Web of Science ®Google Scholar
• Isakova T, Wahl P, Vargas GS, Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-80
   PubMed Web of Science ®Google Scholar
• Nakano C, Matsui I, Tomida S, Combination use of vitamin D status and FGF23 for risk strafication of renal outcome. Clin J Am Soc Nephrol 2012;7:810-19
   PubMed Web of Science ®Google Scholar
• Oliveira RB, Cancela AL, Graciolli FG, Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010;5(2):286-91
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Caglar S, Gradowska L, On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using “proportional reduction” of dietary phosphorus intake. Kidney Int 1972;2:147-51
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Tamada T, Kasai N, Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 2008;23:1509-18
   PubMed Web of Science ®Google Scholar
• Shalhoub V, Shatzen EM, Ward SC, FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012;122:2543-453
   PubMed Web of Science ®Google Scholar
• Ketteler M, Biggar PH, Liangos O. FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. Nephrol Dial Transplant 2012; Epub ahead of print
   Web of Science ®Google Scholar
• Block GA, Wheeler D, Persky MS, Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23:1407-15
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Gutekunst L, Mehorotra R, Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5:519-30
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Komaba H, Miyamoto K-I. Editorial: source matters: from phosphorus load to bioavailability. Clin J Am Soc Nephrol 2011;6:239-40
   PubMed Web of Science ®Google Scholar
• Ritz E, Hahn K, Ketteler M, Phosphate additives in food: a health risk. Dtsch Arztebl Int 2012;109:49-55
   PubMed Web of Science ®Google Scholar
• Sullivan C, Sayre SS, Leon JB, Effect of food additives on hyperphosphatemia among patients with end-stage renal disease. JAMA 2009;301:629-35
   PubMed Web of Science ®Google Scholar
• Bammens B, Evenepoel P, Verbenke K, Removal of middle molecules and protein bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003;64:2238-43
   PubMed Web of Science ®Google Scholar
• Ayus JC, Mizani MR, Achinger SG, Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective controlled study. J Am Soc Nephrol 2005;16:2778-88
   PubMed Web of Science ®Google Scholar
• Pierratos A, Ouwendyk M, Francoeur R, Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998;9:859-68
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Weerts C, Loppez-Hilker S, Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315:157-61
   PubMed Web of Science ®Google Scholar
• Delmez JA, Tindira CA, Windus DW, Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992;3:96-102
   PubMed Web of Science ®Google Scholar
• Jamal SA, Fitchett D, Lok CE, The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 2009;24:3168-74
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Lazanus JM, Poly[allylamine hydrochloride] (Rena Gel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71
   PubMed Web of Science ®Google Scholar
• Delmez J, Block G, Robertson J, A randomized double-blind crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-91
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J, Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24
   PubMed Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41
   PubMed Web of Science ®Google Scholar
• Suki WN, Zabaneh R, Cangiano JL, Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7
   PubMed Web of Science ®Google Scholar
• Quinbi W, Moustafa M, Muenz LR, A 1 year randomized trial of calcium acetate versus sevalamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calciu Acetate Renage; Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65
   PubMed Web of Science ®Google Scholar
• Chertow GW, Raggi P, McCarthy JT, The effects of sevelamer and calcium acetate on proproxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-14
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C, Muro de Fuentes M, Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol 2011;6:2272-89
   PubMed Web of Science ®Google Scholar
• Brandenburg VW, Schlieber G, Heussen N, Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010;25:2672-9
   PubMed Web of Science ®Google Scholar
• Kakuta T, Tanaka R, Hyodo T, Sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011;57:422-31
   PubMed Web of Science ®Google Scholar
• Chiang SS, Chen JB, Yang QC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005;63:461-70
   PubMed Web of Science ®Google Scholar
• Sprague ST, Abboud H, Qiu P, Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009;4:178-85
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Barnett ME, Krause R, Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008;110:c15-23
   PubMed Web of Science ®Google Scholar
• Nikolov IG, Joki N, Nguyen-Khoa T, Lanthanum carbonate, like sevelamer-HCL, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant 2012;27:505-13
   PubMed Web of Science ®Google Scholar
• Toussaint ND, Lan KK, Polkinghorne KR, Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in hemodialysis: a pilot randomized controlled trial. Nephrology 2011;16:290-8
   PubMed Web of Science ®Google Scholar
• Fraile P, Cacharro LM, Garcia-Cosmes P, Encephalopathy caused by lanthanum carbonate. NDT Plus 2011;4:192-4
   PubMedGoogle Scholar
• Kurihara S, Tsuruta Y, Akizawa T. Effect of MCI-106 (colestilan) as a phosphate binder on hyperphosphatemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant 2005;20:424-30
   PubMed Web of Science ®Google Scholar
• Locattelli F, Dimkovic N, Pontoriero G, Effect of MCI-196 on serum phosphate and cholesterol levels. Nephrol Dial Transplant 2010;25:574-81
   PubMed Web of Science ®Google Scholar
• Akizawa T, Ogigasa H, Kameoka C, A phase III, sevelamer HCl-controlled study of bixalomer in chronic kidney disease patients on hemodialysis with hyperphosphatemia (abstract) FR-PO1669. ASN Kidney Week; 2011
   Google Scholar
• Akizawa T, Kameoka C; Bixalomer Study Group. Long-term treatment of bixalomer in chronic kidney disease patients on hemodialysis with hyperphosphatemia (abstract). FR-PO1667. ASN Kidney Week; 2011
   Google Scholar
• Yokoyama K, Hirakata H, Akiba T, Effect of oral JTT-751. Ferric Citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 2012;36:478-87
   PubMed Web of Science ®Google Scholar
• Sinsaku M, Sika M, Koury M, The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 2012;121:c25-9
   PubMedGoogle Scholar
• Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 2010;74:4-11
   PubMed Web of Science ®Google Scholar
• Wuthrich RP, Chonchol M, Covic A, Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013;8(2):280-9
   PubMed Web of Science ®Google Scholar
• Block GA, Brillhart SL, Persky MS, Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int 2010;77:897-903
   PubMed Web of Science ®Google Scholar
• Chen JB, Chiang SS, Chen HC, Efficacy and safety of SBR759, a novel iron (III)-based phosphate binder, in patients undergoing hemodialysis: a 12 week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology 2011;16:743-50
   PubMed Web of Science ®Google Scholar
• McIntyre CW, Pai P, Warwick G, Iron-magnesium hydroxycarbonate (Fermagate): a novel non-calcium containing phosphate binder for the treatment of hyperphosphatemia in chronic dialysis patients. Clin J Am Soc Nephrol 2009;4:401-9
   PubMed Web of Science ®Google Scholar
• De Francisco ALM, Leidig M, Covic A, Evaluation of calcium acetate/magnecium carbonate as a phosphate binder compared with sevelamer hydrochloride in hemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25:3707-17
   PubMed Web of Science ®Google Scholar
• Shimoda K, Akiba T, Matsushima T, Niceritrol decreases serum phosphate levels in chronic dialysis patients. Nihon Jinzo Gakkai Shi (Japanese) 1998;40:1-7
   PubMedGoogle Scholar
• Takahashi Y, Tanaka A, Nakamura T, Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004;65:1099-104
   PubMed Web of Science ®Google Scholar
• Cheng SC, Young DO, Huang Y, A randomized, double blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1131-8
   PubMed Web of Science ®Google Scholar
• Kuboyama N, Watanabe Y, Yamaguchi M, Effect of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 1999;14:610-14
   PubMed Web of Science ®Google Scholar
• Katai K, Tanaka H, Tatsumi S, Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999;14:1195-201
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Smith CP, Brechley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011;7:578-89
   PubMed Web of Science ®Google Scholar
• Adenas MD, Malek T, Gil MT, Challenge of phosphorus control in hemodialysis patients: a adherence? J Nephrol 2010;23:525-34
   PubMed Web of Science ®Google Scholar
• Goto S, Komaba H, Moriwaki K, Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol 2011;6:1375-84
   PubMed Web of Science ®Google Scholar
• Tanaka H, Hamano T, Fujii N, The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone 2009;45:949-55
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Komaba H, Hamano T. Vitamin D supplement in renal disease: is calcitriol all that needed? Scand J Clin Lab Invest 2012;72(Suppl 243):120-3
   Google Scholar
• de Zeeuw D, Agarwal R, Amdahl M, Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a rondamized controlled trial. Lancet 2010;376:1543-51
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhang W, Zhang X, Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012;7:391-400
   PubMed Web of Science ®Google Scholar
• Thadhani R, Appelbaum E, Pritchett Y, Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674-84
   PubMed Web of Science ®Google Scholar
• Tamez H, Zoccali C, Packham D, Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 2012;164:902-9
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int 2006;70(Suppl 102):S3-7
   PubMed Web of Science ®Google Scholar
• Sprague SM, Llach F, Amdahl M, Paricaicitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-90
   PubMed Web of Science ®Google Scholar
• Akizawa T, Suzuki M, Akiba T, Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001;38(Suppl 1):S147-51
   PubMedGoogle Scholar
• Hayashi M, Tsuchiya Y, Itaya Y, Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicenter trial. Nephrol Dial Transplant 2004;19:2063-73
   Web of Science ®Google Scholar
• Block GA, Martin KJ, de Francisco AL, Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Yumita S, Akizawa T, Cinacalcet (KRN 1493) effectively decreases serum intact PTH level with favorable control of serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008;23:328-35
   PubMed Web of Science ®Google Scholar
• Komaba H, Nakanishi S, Fujimori A, Cinacalcet effectively reduces parathyroid hormone secretion and gland hyperplasia regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010;5:2305-14
   PubMed Web of Science ®Google Scholar
• Cunningham J, Danese M, Olseon K, Effects of calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Fukuma S, Onishi Y, Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Clin J Am Soc Nephrol 2012;7:1473-80
   PubMed Web of Science ®Google Scholar
• Komaba H, Moriwaki K, Goto S, Cost effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2012;60:262-71
   PubMed Web of Science ®Google Scholar
• Raggi P, Chertow GM, Torres PU, The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011;26:1327-39
   PubMed Web of Science ®Google Scholar
• EVOLVE Trial Invsetigators. Chertow GM, Block GA, Correa-Rotter R, Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-94
   PubMed Web of Science ®Google Scholar
• Baruch A, Maclean D, Yin K, KAI-4169, a novel calcimimetics for the treatment for secondary hyperparathyroidism. Endocr Rev 2011;32(03_Meeting Abstracts):P2-98
   Google Scholar
• Shiizaki K, Hatamura I, Fukagawa M, Development of a technique for introduction of an expressed cDNA into parathyroid cells by direct injection. Endocrinology 2010;151:4031-8
   PubMed Web of Science ®Google Scholar
• Kanai G, Kakuta T, Sawada K, Suppression of parathyroid hormone production in vitro and in vivo by RNA interference. Kidney Int 2009;75:490-8
   PubMed Web of Science ®Google Scholar
• Kakuta T, Fukagawa M, Fujisaki T, Prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999;33:1091-9
   PubMed Web of Science ®Google Scholar
• Kitaoka M, Fukagawa M, Fukuda N, Direct injections of calcitriol into parathyroid hyperplasia in chronic dialysis patients with severe parathyroid hyperfunction. Nephrology 1995;1:563-8
   Google Scholar